Chuan Ning Biotech announced that the controlling shareholder Colon Pharmaceutical and Colon Ning Hui, which it controls, have issued a letter of commitment to voluntarily extend the limited sale period of the company's shares by one year before the initial launch. Colon Pharmaceuticals holds 1.57 billion shares, accounting for 70.40% of the total share capital. The original sales restriction period was until December 27, 2025, and the extended deadline was December 27, 2026. Clenninghui held 40 million shares, accounting for 1.79% of the total share capital. The original sales restriction period also ended on December 27, 2025, and the extended deadline was December 27, 2026. During the sales restriction period, the acquisition of new shares due to the company's actions is also subject to the sales restriction agreement.

Chuan Ning Biotech announced that the controlling shareholder Colon Pharmaceutical and Colon Ning Hui, which it controls, have issued a letter of commitment to voluntarily extend the limited sale period of the company's shares by one year before the initial launch. Colon Pharmaceuticals holds 1.57 billion shares, accounting for 70.40% of the total share capital. The original sales restriction period was until December 27, 2025, and the extended deadline was December 27, 2026. Clenninghui held 40 million shares, accounting for 1.79% of the total share capital. The original sales restriction period also ended on December 27, 2025, and the extended deadline was December 27, 2026. During the sales restriction period, the acquisition of new shares due to the company's actions is also subject to the sales restriction agreement.